Published in Infect Dis Clin North Am on March 01, 2007
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet (2010) 3.90
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97
Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA (2010) 1.67
Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav (2010) 1.29
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis (2013) 1.24
Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy (2010) 1.17
Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13
Emergency department utilization among a cohort of HIV-positive injecting drug users in a Canadian setting. J Emerg Med (2011) 1.08
Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia. Am J Drug Alcohol Abuse (2010) 1.03
Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse (2009) 1.02
Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users. HIV Med (2012) 0.98
Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health (2011) 0.90
Management of HIV infection in patients with substance use problems. Curr Infect Dis Rep (2008) 0.90
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy (2015) 0.88
Exploring How Substance Use Impedes Engagement along the HIV Care Continuum: A Qualitative Study. Front Public Health (2016) 0.83
Mechanism(s) involved in opioid drug abuse modulation of HAND. Curr HIV Res (2012) 0.83
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend (2009) 0.83
Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. Br J Pharmacol (2009) 0.82
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. Ther Drug Monit (2011) 0.81
Substance use in older HIV-infected patients. Curr Opin HIV AIDS (2014) 0.79
Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment. J Acquir Immune Defic Syndr (2015) 0.77
Psychosocial factors in adherence to antiretroviral therapy among HIV-positive people who use drugs. Health Psychol (2015) 0.77
Integrated HIV care and service engagement among people living with HIV who use drugs in a setting with a community-wide treatment as prevention initiative: a qualitative study in Vancouver, Canada. J Int AIDS Soc (2017) 0.76
Burden and nutritional deficiencies in opiate addiction- systematic review article. Iran J Public Health (2014) 0.75
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Curr Vasc Pharmacol (2016) 0.75
HIV Patients' Preference for Integrated Models of Addiction and HIV Treatment in Vietnam. J Subst Abuse Treat (2016) 0.75
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA (2006) 13.15
Alcohol and public health. Lancet (2005) 10.82
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry (2001) 7.30
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med (2000) 6.65
Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr (1993) 5.08
The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med (1994) 4.87
Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 3.86
Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry (2004) 3.72
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology (2005) 3.53
Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA (1998) 3.00
Methadone maintenance reduces injecting in prison. BMJ (1996) 2.94
Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 2.88
Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med (2002) 2.74
Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr (2006) 2.72
Eleven years of community-based directly observed therapy for tuberculosis. JAMA (1995) 2.27
Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med (2006) 2.26
WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry (1994) 2.25
The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. Int J STD AIDS (2003) 2.12
Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. Int J STD AIDS (2003) 2.07
Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Educ Prev (2003) 2.03
Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry (1991) 2.00
One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction (2000) 1.93
Quality of life among women living with HIV: the importance violence, social support, and self care behaviors. Soc Sci Med (2001) 1.89
Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS (2001) 1.88
Medications development: successes and challenges. Pharmacol Ther (2005) 1.80
Agents in development for the management of cocaine abuse. Drugs (2004) 1.77
A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend (2004) 1.75
High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr (2002) 1.75
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73
Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis (2004) 1.72
Rifampin-induced methadone withdrawal. N Engl J Med (1976) 1.70
HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect (2003) 1.69
Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend (2003) 1.68
Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatry (2004) 1.67
Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction (2000) 1.66
Triple diagnosis: dual diagnosis and HIV disease, part 2. AIDS Read (2003) 1.58
Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry (2000) 1.55
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis (2006) 1.52
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend (2003) 1.50
Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis (2001) 1.50
Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis (2002) 1.46
The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr (2005) 1.46
Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs (2005) 1.43
Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs (1988) 1.41
Keeping it together: stigma, response, and perception of risk in relationships between drug injectors and crack smokers, and other community residents. AIDS Care (2005) 1.37
Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.36
Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr (2006) 1.33
Mechanisms of HIV-1 neurotropism. Curr HIV Res (2006) 1.33
Injection drug use and human immunodeficiency virus infection. Clin Infect Dis (1995) 1.31
Strategies for primary HIV prevention that target behavioral change. Clin Infect Dis (2007) 1.31
Opioid substitution and HIV/AIDS treatment and prevention. Lancet (2004) 1.28
The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis (2006) 1.28
Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health (2005) 1.25
The impact of needle exchange-based health services on emergency department use. J Gen Intern Med (2002) 1.22
A population-based study examining the emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 in New York City. Ann Clin Microbiol Antimicrob (2006) 1.22
Neurocognitive aspects of medication adherence in HIV-positive injecting drug users. AIDS Behav (2006) 1.22
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol (2001) 1.16
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (1999) 1.15
Hepatitis C infection among drug users in northern Thailand. Am J Trop Med Hyg (2006) 1.14
Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health (2005) 1.14
Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs (2003) 1.13
A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction (2005) 1.11
Clinical management of depression and anxiety in HIV-infected adults. AIDS (2005) 1.11
High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) (2002) 1.09
HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected U.S. cities. J Acquir Immune Defic Syndr (1991) 1.09
Alcohol use severity and HIV sexual risk among juvenile offenders. Subst Use Misuse (2006) 1.08
Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis (2006) 1.08
HIV/AIDS--dominant player in chronic kidney disease. Ethn Dis (2006) 1.03
Hepatitis C virus infection and neurocognitive function. Neurology (2006) 1.03
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction (2003) 1.00
Hepatitis C infection is associated with depressive symptoms in HIV-infected adults with alcohol problems. Am J Gastroenterol (2006) 0.98
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health (2003) 0.98
Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health (2003) 0.98
Substance abuse and the kidney. QJM (2000) 0.97
Drugs of abuse and renal disease. Curr Opin Nephrol Hypertens (1996) 0.97
Recreational drug use: a neglected risk factor for end-stage renal disease. Am J Kidney Dis (2001) 0.97
Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol (2004) 0.96
Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment--United States, 1987-1989. MMWR Morb Mortal Wkly Rep (1990) 0.96
HIV and stigma: analysis and research program. Curr HIV/AIDS Rep (2005) 0.96
Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS (2006) 0.95
Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther (1996) 0.94
Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol (2003) 0.94
Targeting HIV prevention on African American crack and injection drug users. Subst Use Misuse (2003) 0.93
Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict (2001) 0.93
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep (2006) 0.91
Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend (1983) 0.91
Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clin Pharmacokinet (2005) 0.90
The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther (1998) 0.90
Effectiveness of methadone maintenance for heroin addiction. Psychol Rep (1998) 0.89
Depression in HIV-infected patients: allopathic, complementary, and alternative treatments. J Psychosom Res (2004) 0.89
Nephropathy associated with heroin abuse in Caucasian patients. Nephrol Dial Transplant (2003) 0.88
Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend (1995) 0.87
Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat (2007) 0.87
HIV infection in intravenous drug abusers in Berlin: risk factors and time trends. Klin Wochenschr (1990) 0.86
Needle sharing and high-risk sexual behaviors among IV drug users in Southern Thailand. AIDS Patient Care STDS (1998) 0.86
HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS (2000) 0.86
Buprenorphine: high-affinity binding to dorsal spinal cord. J Neurochem (1982) 0.86
The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics (2000) 0.86
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis (2004) 6.27
Effect of Ebola progression on transmission and control in Liberia. Ann Intern Med (2014) 3.96
A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend (2010) 2.38
Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis (2011) 2.12
Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health (Larchmt) (2011) 2.10
Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep (2005) 1.76
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73
Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med (2002) 1.66
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health (2010) 1.66
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65
Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis (2006) 1.55
Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS (2011) 1.52
Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: the LifeWindows Project. AIDS Behav (2011) 1.49
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse (2010) 1.48
Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. J Acquir Immune Defic Syndr (2010) 1.47
HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Int J Drug Policy (2007) 1.40
Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials (2007) 1.39
Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav (2013) 1.39
A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep (2012) 1.37
Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One (2012) 1.37
Understanding the revolving door: individual and structural-level predictors of recidivism among individuals with HIV leaving jail. AIDS Behav (2013) 1.35
Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr (2006) 1.33
Routine opt-out HIV testing strategies in a female jail setting: a prospective controlled trial. PLoS One (2009) 1.33
Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav (2013) 1.33
Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ (2013) 1.33
A prospective controlled trial of routine opt-out HIV testing in a men's jail. PLoS One (2009) 1.32
Strategies for primary HIV prevention that target behavioral change. Clin Infect Dis (2007) 1.31
HIV control efforts should directly address incarceration. Lancet Infect Dis (2007) 1.31
Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care (2011) 1.31
Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav (2010) 1.29
Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr (2009) 1.29
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
HIV-related research in correctional populations: now is the time. Curr HIV/AIDS Rep (2011) 1.25
Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis (2013) 1.24
The impact of needle exchange-based health services on emergency department use. J Gen Intern Med (2002) 1.22
Adaptation of an evidence-based intervention targeting HIV-infected prisoners transitioning to the community: the process and outcome of formative research for the Positive Living Using Safety (PLUS) intervention. AIDS Patient Care STDS (2009) 1.22
Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend (2013) 1.15
Early identification of HIV: empirical support for jail-based screening. PLoS One (2012) 1.15
Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. Am J Public Health (2014) 1.15
Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13
Emergency department use by released prisoners with HIV: an observational longitudinal study. PLoS One (2012) 1.11
Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav (2007) 1.11
Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr (2011) 1.10
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09
Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS Behav (2013) 1.09
Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend (2011) 1.09
Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr (2011) 1.09
The association between history of violence and HIV risk: a cross-sectional study of HIV-negative incarcerated women in Connecticut. Womens Health Issues (2007) 1.08
Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav (2013) 1.07
Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users. Subst Abus (2011) 1.06
The diagnostic performance of a single GeneXpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in Malaysia. PLoS One (2013) 1.06
At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine. Addiction (2013) 1.04
Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc (2009) 1.04
HIV testing in correctional institutions: evaluating existing strategies, setting new standards. AIDS Public Policy J (2007) 1.03
Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia. Am J Drug Alcohol Abuse (2010) 1.03
Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend (2013) 1.03
Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr (2011) 1.02
Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse (2007) 1.02
Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse (2009) 1.02
Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav (2013) 1.02
Screening for drug and alcohol use disorders and their association with HIV-related sexual risk behaviors among men who have sex with men in Peru. PLoS One (2013) 1.00
Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One (2013) 1.00
An assessment of health-care students' attitudes toward patients with or at high risk for HIV: implications for education and cultural competency. AIDS Care (2014) 0.99
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials (2011) 0.99
Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr (2007) 0.99
Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat (2012) 0.98
Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach. Clin Infect Dis (2006) 0.96
Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse (2008) 0.96
Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS (2006) 0.95
High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend (2013) 0.95
Being unaware of being HIV-infected is associated with alcohol use disorders and high-risk sexual behaviors among men who have sex with men in Peru. AIDS Behav (2014) 0.94
Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care (2014) 0.93
Next steps for Ukraine abolition of HIV registries, implementation of routine human immunodeficiency virus testing and expansion of services. Addiction (2010) 0.93
Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse (2012) 0.92
The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting. PLoS One (2013) 0.92
Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One (2012) 0.91
High rates of unprotected anal intercourse with regular and casual partners and associated risk factors in a sample of ethnic Malay men who have sex with men (MSM) in Penang, Malaysia. Sex Transm Infect (2013) 0.90
Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse (2011) 0.90
Letter to the editor: regarding "individual and neighborhood correlates of membership in drug-using networks with a higher prevalence of HIV in New York City (2006-2009)". Ann Epidemiol (2013) 0.90
Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health (2014) 0.90
Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers. PLoS One (2012) 0.90
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse (2007) 0.88
Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy. AIDS Behav (2013) 0.88
Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health (2009) 0.88
Partner violence and health among HIV-infected jail detainees. Int J Prison Health (2013) 0.88
Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening. Am J Drug Alcohol Abuse (2009) 0.87
Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat (2007) 0.87
Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. J Acquir Immune Defic Syndr (2015) 0.87
Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model. AIDS Care (2010) 0.87
Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health (2014) 0.87
Editorial comment: why treat three conditions when it is one patient? AIDS Read (2003) 0.86
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions. Arch Intern Med (2010) 0.85
Ukrainian prisoners and community reentry challenges: implications for transitional care. Int J Prison Health (2013) 0.84
Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Rev Clin Pharmacol (2008) 0.84
Frequent emergency department use among released prisoners with human immunodeficiency virus: characterization including a novel multimorbidity index. Acad Emerg Med (2013) 0.84
Communication technology use and mHealth acceptance among HIV-infected men who have sex with men in Peru: implications for HIV prevention and treatment. AIDS Care (2014) 0.84
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend (2009) 0.83
Tuberculosis screening in a novel substance abuse treatment center in Malaysia: implications for a comprehensive approach for integrated care. J Subst Abuse Treat (2013) 0.83